Ozempic for weight loss: what the label says vs. how it is being used
Ozempic became a household name in 2023. But it is technically a diabetes drug — here is how the off-label weight loss story unfolded and what that means if you are considering it.
Key points
- Ozempic is semaglutide, FDA-approved for type 2 diabetes, not weight loss.
- Wegovy is the same molecule at a higher dose, FDA-approved for weight management.
- Off-label prescribing of Ozempic for weight loss is legal but creates real-world friction.
- For a weight loss indication, Wegovy or compounded semaglutide are usually the cleaner path.
Same molecule, different label
Ozempic and Wegovy are both injectable semaglutide, made by Novo Nordisk. The difference is the FDA indication and the approved maximum dose: Ozempic tops out at 2.0 mg weekly for type 2 diabetes; Wegovy goes to 2.4 mg weekly and carries a chronic weight management indication.
Clinically the medication is the same drug. Regulatorily and commercially, they are distinct products.
How Ozempic ended up in the weight loss conversation
When clinicians noticed that patients with diabetes on Ozempic were losing meaningful weight, off-label prescribing for weight loss followed — faster than supply could keep up. That contributed to 2023-2024 shortages that affected both diabetic and weight-loss patients.
Supply has stabilized, but the lesson stuck: if your goal is weight management, there is usually a better-indicated option than chasing an Ozempic prescription.
What to ask your clinician
If your goal is weight loss and you do not have type 2 diabetes, ask specifically about Wegovy, Zepbound, or a compounded alternative your telehealth provider supports. They target the same mechanism with fewer commercial headaches.